Clinical Significance of Galectin-3 Expression in Squamous Cell Carcinoma of Lung

Pokhare, Saraswati; Sharma, Umesh C; Attwood, Kristopher; Mansoor, Sharmeen

doi:10.26502/jcsct.5079169

Cited by 4 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Abnormal galectin-1 levels correlated with decreased overall survival, as depicted in Figure 6 B with no difference for galectins-3 and -9 in Figure 6 C and Figure 6 D, respectively. The lack of differences observed for galectin-3 levels and the differences observed for galectin-1 levels correlate with previous studies [ 22 , 34 , 49 ]. It is of note that there was no difference in OS when galectin-1 levels were separated into low, normal, and high values, as seen in Figure 6 A, albeit it approached significance ( p = 0.0953).…”

Section: Discussionsupporting

confidence: 91%

“…A recent study revealed a correlation between galectin-3 expression and squamous cell lung cancer stage. This finding, which is contrary to our study, might be attributed to the difference in methodologies; we employed ELISA for quantifying galectin-3 levels, whereas IHC was used to assess galectin-3 expression in the previous study [34]. Clinically, the Eighth Edition of TNM classification is utilized for staging NSCLC, but we utilized simple stage classification defined as I, II, III, and IV since we had only one patient with stage IIIC disease and two patients with stage IIIB disease [35,36].…”

Section: Resultscontrasting

confidence: 82%

“…Although the patients that had lower galectin-1 levels were more likely to have previous metastatic disease, serum galectin-1, -3, and -9 levels did not predict future metastasis. Earlier studies have demonstrated that elevated levels detected by ELISA or increased expression of galectin-3 detected by IHC correlate with metastasis [ 24 , 34 ]. We hypothesize that the observed differences are due to our patient population.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Exploratory Assessment of Galectin-1, -3, and -9 in Non-Small Cell Lung Cancer

Shuster,

Funkhouser,

Allen

et al. 2024

Cancers

View full text Add to dashboard Cite

Galectins play a pivotal role in lung cancer oncogenic pathways, influencing apoptosis, angiogenesis, and tumor metastasis. Biomarkers that diagnose, prognose, and guide cancer treatment are crucial, with galectins having the biomarker potential for non-small cell lung cancer (NSCLC). Using enzyme-linked immunosorbent assay (ELISA), we assessed serum galectin-1, -3, and -9 levels in NSCLC patients. A retrospective chart review was performed to examine patient demographics, cancer stage, tumor biology, cancer treatment, and patient outcomes. Galectin levels were then compared across these factors. In this exploratory analysis, galectin-3 levels were significantly lower in patients with squamous cell lung cancer (p = 0.0019) and in patients exposed to chemotherapy (p = 0.0375). Galectin-1 levels were significantly lower in patients with previous metastasis but had no correlation with future metastasis. Abnormal galectin-1 levels were significantly correlated with decreased overall survival (OS) in NSCLC (p = 0.0357) and specifically in patients with surgically resectable NSCLC (p = 0.0112). However, abnormal galectin-1 levels were not found to correlate with decreased OS in multivariable analysis (p = 0.0513). These findings may have clinical implications as galectin-3 inhibitors are in trials for NSCLC. Additionally, they suggest that galectin-1 has potential as a prognostic marker for surgically resectable NSCLC.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Resultscontrasting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Exploratory Assessment of Galectin-1, -3, and -9 in Non-Small Cell Lung Cancer

Shuster,

Funkhouser,

Allen

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…E-mail: aramsurgeon@mail.ru Зыбина Наталья Николаевна -д-р биол. наук, профессор, заведующая отделом лабораторной диагностики 3 ; ORCID: https://orcid.org/0000-0002-5422-2878. E-mail: zybinan@inbox.ru Янушевич Олег Олегович -д-р мед.…”

unclassified

“…Сегодня в качестве одного из перспективных маркеров онкологических заболеваний рассматривается представитель семейства лектинов галектин-3 [2,3]. Идентифицировано 15 галектинов, которые делят на три типа: прототипы галектинов с одним одиночным доменом распознавания углеводов; галектины с тандемными повторами и двумя одиночными доменами распознавания углеводов; галектины химерного типа с одним одиночным доменом распознавания углеводов [4].…”

unclassified

Galectin-3 and matrix metalloproteinases 2 and 9 in peripheral blood of gastric cancer patients

Короткова¹,

Samoilova³

et al. 2023

Almanac of Clinical Medicine

View full text Add to dashboard Cite

Background: High incidence of gastric cancer (GC), its aggressive clinical course, rapid tumor dissemination, low sensitivity to chemotherapy and lack of reliable laboratory diagnostic criteria urgently require a search for the most informative markers associated with key biologic properties of the tumors. Aim: Comparative analysis of galectin-3, matrix metalloproteinase (MMP)-2, and MMP-9 levels in peripheral blood of GC patients and healthy donors, assessment of association of these markers with clinical morphological characteristics of the disease, and prognosis of overall and relapse-free survival. Materials and methods: Sixty (60) primary treatment-nave GC patients (38 men, 22 women) aged 29 to 81 years and 90 healthy donors compatible with their age and sex were included into the study. Galectin-3 was measured in EDTA plasma, MMP-2 and MMP-9 in serum with standard direct enzyme immunoassay kits "Human MMP-2 (total)", "Human MMP-9 (total)", "Human Galectin-3" (RD Systems, USA). Results: Plasma galectin-3 concentration in the GC patients was significantly higher than in the healthy controls (median 12.9 and 10.6 ng/ml, respectively; p 0.0001). No difference in serum MMP-9 levels between GC patients and control subjects were found, while MMP-2 level in the control group was significantly higher, than in the GC patients (p = 0.039). No association between galectin-3, MMP-2, and MMP-9 blood levels in the GC patients could be identified. In contrast to GC patients, there was a positive correlation of plasma galectin-3 with age in the control group (rs = 0.51, p 0.005). No associations between the biomarkers levels in blood and clinical and morphological characteristics of GC were established, except MMP-9 being higher at Т4а invasion depth as compared to the earlier Т2 level. Marked differences in the overall survival depending on plasma galectin-3 levels were found, with the cut-off level of 12.9 ng/ml: the 5-year overall survival in the patients with low galectin-3 was better, than in those with its higher level (50 and 43%, respectively; however, the difference was non-significant, р 0.1). Both overall and relapse-free survival of the GC patients was higher in those with low ( 212 ng/ml) serum MMP-2: the 5-year overall survival in this group comprised 60% versus 23% in the patients with higher MMP-2 (p = 0.018). The difference in relapse-free survival was non-significant. Serum MMP-9 levels had no significant impact on the survival of GC patients. Conclusion: The ambiguous data on the clinical role of galectin-3, MMP-2, MMP-9 in GC obtained in this study indicate the necessity of further investigation of their possible utility for the diagnostics and prognosis of treatment results.

show abstract

Assessment of Prognostic Ability of Galectin-1, -3, and -9 in Lung Cancer Patients

Shuster,

Funkhouser,

Allen

et al. 2023

Preprint

View full text Add to dashboard Cite

Galectins play a role in lung cancer oncogenic pathways including apoptosis, t-cell immune responses, and tumor metastasis. Biomarkers that diagnose, prognose, and assist with treatment remain important, and galectins represent biomarkers that have the potential to impact lung cancer management through these pathways. Using enzyme-linked immunosorbent assay (ELISA) we examined galectin-1, -3, and -9 levels from lung cancer patient serum. Through comprehensive chart review: patient demographics, staging information, tumor biology, treatment data, and outcomes including overall survival (OS) and metastasis were retrospectively collected. Galectin levels were then compared to these numerous factors. Galectin-1, -3, and -9 levels did not correlate with cancer stage, however galectin-3 levels were lower in small cell lung cancer (SCLC) and squamous cell lung cancer than in adenocarcinoma. There was no correlation between galectin levels and previous treatment or future metastasis. Patients that had an abnormal galectin-1 level had decreased OS. Furthermore, patients with curative surgically resectable NSCLC with abnormal galectin-1 levels had decreased OS, but there was no difference in those with SCLC or that were non-resectable treated palliatively. These findings provide insight into galectin levels in various lung cancer histology and highlight the potential for galectin-1 to assist in prognosis of surgically resectable NSCLC.

show abstract

Clinical Significance of Galectin-3 Expression in Squamous Cell Carcinoma of Lung

Cited by 4 publications

References 24 publications

Exploratory Assessment of Galectin-1, -3, and -9 in Non-Small Cell Lung Cancer

Exploratory Assessment of Galectin-1, -3, and -9 in Non-Small Cell Lung Cancer

Galectin-3 and matrix metalloproteinases 2 and 9 in peripheral blood of gastric cancer patients

Assessment of Prognostic Ability of Galectin-1, -3, and -9 in Lung Cancer Patients

Contact Info

Product

Resources

About